ACADIA Pharmaceuticals In... (ACAD)
| Bid | 16.45 |
| Market Cap | 2.77B |
| Revenue (ttm) | 963.99M |
| Net Income (ttm) | 227.92M |
| EPS (ttm) | 1.36 |
| PE Ratio (ttm) | 12.22 |
| Forward PE | 23.45 |
| Analyst | Buy |
| Ask | 17.15 |
| Volume | 1,069,697 |
| Avg. Volume (20D) | 2,368,744 |
| Open | 16.72 |
| Previous Close | 17.07 |
| Day's Range | 16.28 - 16.87 |
| 52-Week Range | 14.15 - 20.68 |
| Beta | 0.43 |
About ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psych...
Analyst Forecast
According to 16 analyst ratings, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is $23, which is an increase of 38.35% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · businesswire.com
Acadia Pharmaceuticals to Participate at Upcoming Investor ConferencesSAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the following virtual investor conferences: UBS Virtual CNS Day 2025 Fireside Chat: M...
1 month ago · seekingalpha.com
ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call TranscriptACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q4 2024 Results Conference Call February 26, 2025 4:30 PM ET Company Participants Al Kildani - SVP of Investor Relations & Corporate Communications Catherine...